Dallas, Texas (PRWEB) February 04, 2015
MicroTransponder, Inc., (http://www.microtransponder.com) a privately-held medical device company is pleased to announce the successful completion of its 20-patient stroke trial using the Vivistim® System. The results of this ground breaking clinical trial for stroke patients who experience limited upper limb mobility following a stroke will be presented during an oral presentation at the International Stroke Conference on Feb. 12 at 2:42 PM in Nashville, Tennessee. The International Stroke Conference is one of the largest gathering of stroke clinicians in the world and is sponsored by the American Heart Association. (http://www.strokeconference.org)
The 20-patient study focused on stroke patients with limited upper limb function following their stroke. The lack of upper limb mobility impeded the ability to do daily tasks and live independently. The study was conducted at 2 stroke centers in the United Kingdom. The principle investigator for the study was Dr. Jesse Dawson, and he explained, “We saw dramatic improvements in these patients over the 6-week treatment period. Some patients were able to resume daily activities like driving, swimming, grocery shopping, cooking, and taking care of young children.”
Based on these successful trial results, MicroTransponder has planned a 20-patient follow up U.S. stroke study. The initial sites will be in Dallas, Texas, Houston, Texas, and Minneapolis, Minnesota. Enrollment is now open and the sites are seeking stroke patients who have recently had a stroke and are still experiencing upper limb movement limitations although they must still have some movement. More information is available at http://www.vnsstroketrial.com.
The Vivistim® System has been developed to treat stroke patients that experience an upper-limb deficit following their stroke. It consists of a small implanted battery and wires that internally connect to the vagus nerve in the neck. During the rehabilitative therapy, the patient receives a small amount of neurostimulation to the vagus nerve to strengthen the neural pathways in the brain. This paired treatment method is based on years of neuroscience research published in peer-reviewed academic journals. More information can be found on http://www.MicroTransponder.com
The invitation for an oral presentation at the International Stroke Conference is an important milestone for the Company notes CEO Frank McEachern, “We are honored to be able to present our clinical trial results to one of the largest gatherings of stroke clinicians in the world. Our mission is to bring this therapy to as many stroke patients as possible. Currently, they have very few options if traditional therapy is not effective.” To support additional U.S. clinical trials and further commercialization work, MicroTransponder plans to raise $5 million in funding this summer. Additional information can be found at http://www.MicroTransponder.com
About MicroTransponder, Inc.
MicroTransponder Inc. (http://www.microtransponder.com) is a medical device development company with a strong neuroscience research focus. An experienced team of scientists and engineers has developed and continue developing neurostimulation technology platforms to treat various forms of neurological diseases, including post stroke motor rehabilitation and tinnitus. MicroTransponder has a substantial neurostimulation-focused R&D program which is able to quickly translate scientific discoveries into clinical therapies.